Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 31, 2015 4:08 PM ET

Biotechnology

Company Overview of Eagle Pharmaceuticals Inc.

Company Overview

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban to treat heparin-induced thrombocytopenia; and Ryanodex injectable suspension for the treatment of malignant hyperthermia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma;; and EP-4104, a dantrolene for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, whi...

50 Tice Boulevard

Suite 315

Woodcliff Lake, NJ 07677

United States

Founded in 2007

36 Employees

Phone:

201-326-5300

Key Executives for Eagle Pharmaceuticals Inc.

Chief Executive Officer, President and Director
Age: 55
Total Annual Compensation: $449.6K
Chief Financial Officer
Age: 62
Total Annual Compensation: $265.9K
Chief Medical Officer and Head of Research & Development
Age: 56
Total Annual Compensation: $303.8K
Chief Scientific Officer
Age: 56
Total Annual Compensation: $352.4K
Compensation as of Fiscal Year 2014.

Eagle Pharmaceuticals Inc. Key Developments

Eagle Pharmaceuticals Inc. Enters into Development and Licensing Agreement with Robert One, LLC

On August 5, 2015, Eagle Pharmaceuticals Inc. entered into Amendment No. 2 to Development and Licensing Agreement with Robert One, LLC to revise the Royalty Rate as defined in the Development and Licensing Agreement, dated as of February 13, 2009, as amended (the Robert Development and Licensing Agreement). The Second Amendment revises the definition of Royalty Rate to mean: (i) 50% with respect to a 505(b)(2) application; (ii) 30% with respect to an ANDA application; and (iii) 25% with respect to the Pemetrexed parenteral formulation.

Eagle Pharmaceuticals Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Eagle Pharmaceuticals Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company's total revenue was $6,002,000 compared to $5,792,000 a year ago. The increase was driven by $1.4 million in net sales of Ryanodex, $600,000 in net sales of diclofenac/misoprostol and a $1.3 million increase in argatroban sales during the 2015 period, coupled with a $300,000 increase in royalty income, offset in part by the absence of license and other income. Loss from operations was $8,335,000 compared to $2,982,000 a year ago. Loss before income tax benefit was $8,330,000 compared to $2,934,000 a year ago. Net loss attributable to common stockholders was $8,177,000 compared to $2,934,000 a year ago. Loss per share attributable to common stockholders basic and diluted was $0.53 compared to $0.21 a year ago. For the six months, the company's total revenue was $42,311,000 compared to $10,796,000 a year ago. Income from operations was $11,755,000 compared to loss from operations of $6,586,000 a year ago. Income before income tax benefit was $11,766,000 compared to loss before income tax benefit of $6,914,000 a year ago. Net income attributable to common stockholders was $11,520,000 compared to net loss attributable to common stockholders of $6,153,000 a year ago. Earnings per share attributable to common stockholders diluted were $0.73 compared to loss per share attributable to common stockholders diluted of $0.54 a year ago.

Eagle Pharmaceuticals Inc. Ratifies the Appointment of BDO USA, LLP as the Independent Registered Public Accounting Firm

Eagle Pharmaceuticals Inc. announced that at its AGM held on August 4, 2015, ratified the appointment of BDO USA, LLP as the independent registered public accounting firm of the Company for 2015.

Similar Private Companies By Industry

Company Name Region
Ampla Pharmaceuticals, Inc. United States
LifeSensors, Inc. United States
Light Biology Inc. United States
Therabron Therapeutics, Inc. United States
Mymetics Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Eagle Pharmaceuticals Inc., please visit www.eagleus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.